Translational Sepsis Research: Spanning the Divide
- PMID: 30113370
- PMCID: PMC6097250
- DOI: 10.1097/CCM.0000000000003271
Translational Sepsis Research: Spanning the Divide
Abstract
Objective: Our knowledge of the molecular mechanisms of sepsis has attained exponential growth. Yet, the pillars of its care remain antibiotics, fluid resuscitation, and physiologic support of failing organ systems. The inability to bring biologic breakthroughs to the bedside is not for lack of effort. Over 60 clinical trials of novel therapies, each heavily supported by the momentum of biologic data suggesting clinical utility, have been conducted and have failed to identify benefit. This mass of "negative" clinical data abut an equally towering mound of knowledge of sepsis biology, which collectively have led investigators to ask, "what happened?"
Data sources: Review of published scientific literature via MEDLINE searches using key terms related to the article topics.
Study selection: Original articles, review articles, and systematic reviews were considered.
Data extraction: Articles were selected for inclusion based upon author consensus.
Data synthesis: Here, we present a synthetic review of some of the challenges in translating experimental animal models of sepsis to the bedside. We commence with the concept that the heterogeneity in the kinetics of the sepsis response serves as an important, often underappreciated but surmountable, source of translational impedance. Upon this groundwork, we discuss distinctions between animal experimentation and clinical trial design in the elements for hypothesis testing: cohort selection, power and sample size, randomization and blinding, and timing of intervention. From this concept, we develop a contextual framework for advancing the paradigm of animal-based investigations to facilitate science that transitions from molecule to medicine.
Conclusions: A persistent divide exists between the laboratory and clinical research arenas, which may be addressable via systematic targeting of identified translational gaps.
Conflict of interest statement
The authors report no additional conflicts.
Figures

Similar articles
-
Bench-to-Bedside: A Translational Perspective on Murine Models of Sepsis.Surg Infect (Larchmt). 2018 Feb/Mar;19(2):137-141. doi: 10.1089/sur.2017.308. Epub 2018 Feb 2. Surg Infect (Larchmt). 2018. PMID: 29394153 Free PMC article. Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis.Crit Care Med. 1996 Dec;24(12):2059-70. doi: 10.1097/00003246-199612000-00021. Crit Care Med. 1996. PMID: 8968277 Review.
-
Sepsis therapies: learning from 30 years of failure of translational research to propose new leads.EMBO Mol Med. 2020 Apr 7;12(4):e10128. doi: 10.15252/emmm.201810128. Epub 2020 Mar 16. EMBO Mol Med. 2020. PMID: 32176432 Free PMC article. Review.
Cited by
-
Clinically relevant model of pneumococcal pneumonia, ARDS, and nonpulmonary organ dysfunction in mice.Am J Physiol Lung Cell Mol Physiol. 2019 Nov 1;317(5):L717-L736. doi: 10.1152/ajplung.00132.2019. Epub 2019 Sep 11. Am J Physiol Lung Cell Mol Physiol. 2019. PMID: 31509438 Free PMC article.
-
Of mice and men: Laboratory murine models for recapitulating the immunosuppression of human sepsis.Front Immunol. 2022 Aug 5;13:956448. doi: 10.3389/fimmu.2022.956448. eCollection 2022. Front Immunol. 2022. PMID: 35990662 Free PMC article. Review.
-
Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis.Intensive Care Med Exp. 2020 Feb 4;8(1):7. doi: 10.1186/s40635-019-0290-x. Intensive Care Med Exp. 2020. PMID: 32020483 Free PMC article.
-
Stressed erythrophagocytosis induces immunosuppression during sepsis through heme-mediated STAT1 dysregulation.J Clin Invest. 2021 Jan 4;131(1):e137468. doi: 10.1172/JCI137468. J Clin Invest. 2021. PMID: 32941182 Free PMC article.
-
Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB.Front Immunol. 2018 Dec 18;9:2996. doi: 10.3389/fimmu.2018.02996. eCollection 2018. Front Immunol. 2018. PMID: 30619349 Free PMC article.
References
-
- Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310. - PubMed
-
- Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055–64. - PubMed
-
- Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. - PubMed
-
- Abraham E, Laterre P-F, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332–41. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical